424 A phase 1b/2 randomized study of AVB-S6–500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment
Kathryn E. Beckermann(Vanderbilt University Medical Center), Eric Jonasch(The University of Texas MD Anderson Cancer Center), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center), Vanessa Esquibel(NatureServe), Moshe Chaim Ornstein(Cleveland Clinic), Neil J. Shah(Memorial Sloan Kettering Cancer Center), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Eduardo J. Pennella(Mylan (United States)), Randy L. Anderson(University of North Carolina Wilmington), Xīn Gào(Qingdao University), Mao Shifeng(Allegheny Health Network), Reshma Rangwala(Genmab (United States)), Hans J. Hammers(Southwestern Medical Center), David F. McDermott(Beth Israel Deaconess Medical Center)
Cited by 2
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k